Precision Medicine in Oncology®

Francisco J. Esteva, MD, PhD, discusses how NGS sequencing, PIK3CA-targeted therapies, and ADCs are reshaping treatment in HR+/HER2– breast cancer.

Here is your snapshot of all treatment options that the FDA cleared in November 2024 spanning tumor types.

In case you missed any, read a recap of every episode of OncLive On Air that aired in November 2024.

Rimas V. Lukas, MD, discusses the potential role for eflornithine plus lomustine in recurrent grade 3 IDH-mutant astrocytoma.

Perioperative vorasidenib or ivosidenib demonstrated sustained clinical benefit in patients with predominantly non-enhancing IDH1-mutant diffuse glioma.

The FDA approved the PATHWAY HER2 (4B5) test to identify patients with HER2-positive biliary tract cancer who are eligible for treatment with zanidatamab.

Anita Scheuber, MD, PhD, details how HPK1 inhibition may enhance the antitumor activity of ICIs in solid tumors, diving into the agent NDI-101150 in particular.

The FDA granted fast track designation to ALE.P02 for CLDN1-positive squamous solid tumors.

The FDA has approved revumenib (Revuforj) for the treatment of adult and pediatric patients aged 1 year and older with relapsed or refractory acute leukemia and a KMT2A translocation.

The CHMP has recommended repotrectinib for ROS1-positive non–small cell lung cancer and NTRK-positive solid tumors.

Revumenib met the CR/CRh primary end point of the phase 2 AUGMENT-101 trial in NPM1-mutated acute myeloid leukemia.

Jessica Donington, MD, MSCR, Melina Elpi Marmarelis, MD, and Ibiayi Dagogo-Jack, MD, on when to conduct biomarker testing in NSCLC.

Investigators who champion patient-partnered cancer research have experienced challenges to their effective implementation.

Preclinical data suggest that DLL3-TOPAbody has antitumor activity and could provide a survival advantage in DLL3-expressing tumor cells, including SCLC.

A new drug application has been submitted to the FDA for sunvozertinib in pretreated EGFR exon 20–positive advanced non–small cell lung cancer.

Jessica Donington, MD, MSCR, Melina Elpi Marmarelis, MD, and Ibiayi Dagogo-Jack, MD, on biomarker testing in metastatic or resectable non–small cell lung cancer.

Thach-Giao Truong, MD, discusses the ImmunoCobiVem trial of early switch from targeted therapy to immunotherapy in advanced BRAF V600–positive melanoma.

Aparna Parikh, MD, discusses currently available treatment options for patients with HER2-positive colorectal cancer.

Noman Ashraf, MD, discusses notable data seen with T-DXd treatment in previously treated HER2-mutated and -overexpressing non–small cell lung cancer.

Brian A. Van Tine, MD, PhD, and David S. Hong, MD, discuss the MAGEA4 pathway and the FDA approval of afami-cel in synovial sarcoma.

Daniel E. Haggstrom, MD, discusses future research directions within EGFR-and ALK-mutant non–small cell lung cancer.

Here is your snapshot of all therapeutic options that the FDA approved in October 2024 spanning tumor types.

Asciminib gets FDA accelerated approval for chronic-phase CML, RMC-9805 shows activity in KRAS G12D+ pancreatic cancer, and more from OncLive this week.

In case you missed any, read a recap of every episode of OncLive On Air that aired in October 2024.

Daniel E. Haggstrom, MD discusses the role of osimertinib for patients with unresectable EGFR-mutated non-small cell lung cancer.

First-line sugemalimab plus chemotherapy has received UK approval for metastatic NSCLC without EGFR-sensitizing mutations or ALK/ROS1/RET alterations.

The FDA has extended the PDUFA date for sotorasib plus panitumumab application in KRAS G12C+ metastatic colorectal cancer.

For more first-hand insights, head over to our YouTube channel to watch Dr Markman discuss the inner workings of oncology: https://rb.gy/bvumdn.

Gregory J. Riely, MD, PhD, and Benjamin Besse, MD, discuss unmet needs and future research directions in ALK-positive and ROS1-positive NSCLC.

Gregory J. Riely, MD, PhD, and Benjamin Besse, MD, discuss data for lorlatinib in ROS1-positive NSCLC after crizotinib and chemotherapy.